Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations

被引:48
|
作者
Cevik, Dilek [1 ,2 ]
Yildiz, Gokhan [1 ,2 ]
Ozturk, Mehmet [1 ,2 ,3 ]
机构
[1] Bilkent Univ, Dept Mol Biol & Genet, BilGen Genet & Biotechnol Ctr, TR-06800 Ankara, Turkey
[2] Univ Grenoble 1, INSERM, Ctr Rech, U823, F-38706 La Tronche, France
[3] Dokuz Eylul Univ, Adv Biomed Res Ctr, TR-35340 Izmir, Turkey
关键词
Hepatocellular carcinoma; Liver cancer; Telomerase reverse transcriptase; Promoter mutation; Cellular immortality; Telomerase reverse transcriptase gene; HIGH-FREQUENCY; LIVER CANCERS; CELLS; MECHANISMS;
D O I
10.3748/wjg.v21.i1.311
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To determine the mutation status of human telomerase reverse transcriptase gene (TERT) promoter region in hepatocellular carcinoma (HCC) from different geographical regions. METHODS: We analyzed the genomic DNA sequences of 59 HCC samples comprising 15 cell lines and 44 primary tumors, collected from patients living in Asia, Europe and Africa. We amplified a 474 bp DNA fragment of the promoter region of TERT gene including the 1295228 and 1295250 sequence of chromosome 5 by using PCR. Amplicons were then sequenced by Sanger technique and the sequence data were analyzed with by using DNADynamo software in comparison with wild type TERT gene sequence as a reference. RESULTS: The TERT mutations were found highly frequent in HCC. Eight of the fifteen tested cell lines displayed C228T mutation, and one had C250T mutation with a mutation frequency up to 60%. All of the mutations were heterozygous and mutually exclusive. Ten out of forty-four tumors displayed C228T mutation, and additional five tumors had C250T mutation providing evidence for mutation frequency of 34% in primary tumors. Considering the geographic origins of HCC tumors tested, TERT promoter mutation frequencies were higher in African (53%), when compared to non-African (24%) tumors (P = 0.056). There was also a weak inverse correlation between TERT promoter mutations and murine double minute 2 single nucleotide polymorphism 309 TG polymorphism (P = 0.058). Mutation frequency was nearly two times higher in established HCC cell. CONCLUSION: TERT promoter is one of most frequent mutational targets in liver cancer, and hepatocellular carcinogenesis is highly associated with the loss of telomere-dependent cellular senescence control.
引用
收藏
页码:311 / 317
页数:7
相关论文
共 50 条
  • [41] Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical Implications
    Liu, Tiantian
    Yuan, Xiaotian
    Xu, Dawei
    GENES, 2016, 7 (07):
  • [42] Modulation of human telomerase reverse transcriptase in hepatocellular carcinoma
    Chen, Cheng-Jueng
    Kyo, Satoru
    Liu, Yao-Chi
    Cheng, Yeung-Leung
    Hsieh, Chung-Bao
    Chan, De-Chuan
    Yu, Jyh-Cherng
    Harn, Horng-Jyh
    WORLD JOURNAL OF GASTROENTEROLOGY, 2004, 10 (05) : 638 - 642
  • [43] Characteristics of the isocitrate dehydrogenase gene and telomerase reverse transcriptase promoter mutations in gliomas in Chinese patients
    Qu, Chong-Xiao
    Ji, Hong-Ming
    Shi, Xiang-Cheng
    Bi, Hong
    Zhai, Li-Qin
    Han, De-Wu
    BRAIN AND BEHAVIOR, 2020, 10 (04):
  • [44] Association Between Telomerase Reverse Transcriptase Promoter Mutations and Melanoma Prognosis A Meta-Analysis
    Li, Qing
    Zhang, Jinzhan
    Li, Tingting
    Kang, Xiaojing
    ANALYTICAL AND QUANTITATIVE CYTOPATHOLOGY AND HISTOPATHOLOGY, 2021, 43 (04): : 255 - 268
  • [45] Telomerase reverse transcriptase gene amplification in hepatocellular carcinoma
    Takuma, Y
    Nouso, K
    Kobayashi, Y
    Nakamura, S
    Tanaka, H
    Matsumoto, E
    Fujikawa, T
    Suzuki, M
    Hanafusa, T
    Shiratori, Y
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2004, 19 (11) : 1300 - 1304
  • [46] Modulation of human telomerase reverse transcriptase in hepatocellular carcinoma
    Cheng-Jueng Chen Satoru Kyo Yao-Chi Liu Yeung-Leung Cheng Chung-Bao Hsieh De-Chuan Chan Jyh-Cherng Yu Horng-Jyh Harn Division of General Surgery
    World Journal of Gastroenterology, 2004, (05) : 638 - 642
  • [47] Expression of telomerase catalytic component, telomerase reverse transcriptase, in human gastric carcinomas
    Yasui, W
    Tahara, H
    Tahara, E
    Fujimoto, J
    Nakayama, J
    Ishikawa, F
    Ide, T
    Tahara, E
    JAPANESE JOURNAL OF CANCER RESEARCH, 1998, 89 (11): : 1099 - 1103
  • [48] High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions (vol 4, 2218, 2013)
    Nault, Jean Charles
    Mallet, Maxime
    Pilati, Camilla
    Calderaro, Julien
    Bioulac-Sage, Paulette
    Laurent, Christophe
    Laurent, Alexis
    Cherqui, Daniel
    Balabaud, Charles
    Zucman-Rossi, Jessica
    NATURE COMMUNICATIONS, 2013, 4
  • [49] Pleuroparenchymal fibroelastosis associated with telomerase reverse transcriptase mutations
    Newton, Chad A.
    Batra, Kiran
    Torrealba, Jose
    Meyer, Keith
    Raghu, Ganesh
    Garcia, Christine Kim
    EUROPEAN RESPIRATORY JOURNAL, 2017, 49 (05)
  • [50] Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease
    Donati, Benedetta
    Pietrelli, Alessandro
    Pingitore, Piero
    Dongiovanni, Paola
    Caddeo, Andrea
    Walker, Lucy
    Baselli, Guido
    Pelusi, Serena
    Rosso, Chiara
    Vanni, Ester
    Daly, Ann
    Mancina, Rosellina Margherita
    Grieco, Antonio
    Miele, Luca
    Grimaudo, Stefania
    Craxi, Antonio
    Petta, Salvatore
    De Luca, Laura
    Maier, Silvia
    Soardo, Giorgio
    Bugianesi, Elisabetta
    Colli, Fabio
    Romagnoli, Renato
    Anstee, Quentin M.
    Reeves, Helen L.
    Fracanzani, Anna Ludovica
    Fargion, Silvia
    Romeo, Stefano
    Valenti, Luca
    CANCER MEDICINE, 2017, 6 (08): : 1930 - 1940